# ARIXTRA Local Study For Registration In China.

> **NCT00328939** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 240 (—)

## Conditions studied

- Thromboembolism
- Knee Replacement
- Hip Replacement

## Interventions

- **DRUG:** ARIXTRA infusion
- **DRUG:** Enoxaparine infusion

## Key facts

- **NCT ID:** NCT00328939
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 240 (—)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328939, "ARIXTRA Local Study For Registration In China.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00328939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*